A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates
Czoty, Paul W.
Sukhtankar, Devki D.
Nader, Michael A.
Husbands, Stephen M.
N/ofq peptide receptor
Mu opioid peptide receptor
Subject Categories::B200 Pharmacology, Toxicology and Pharmacy
MetadataShow full item record
AbstractDespite the critical need, no previous research has substantiated safe opioid analgesics without abuse liability in primates. Recent advances in medicinal chemistry have led to the development of ligands with mixed mu opioid peptide (MOP)/nociceptin-orphanin FQ peptide (NOP) receptor agonist activity to achieve this objective. BU08028 is a novel orvinol analog that displays a similar binding profile to buprenorphine with improved affinity and efficacy at NOP receptors. The aim of this preclinical study was to establish the functional profile of BU08028 in monkeys using clinically used MOP receptor agonists for side-by-side comparisons in various wellhoned behavioral and physiological assays. Systemic BU08028 (0.001-0.01 mg/kg) produced potent long-lasting (i.e., >24 h) antinociceptive and antiallodynic effects, which were blocked by MOP or NOP receptor antagonists. More importantly, the reinforcing strength of BU08028 was significantly lower than that of cocaine, remifentanil, or buprenorphine in monkeys responding under a progressive-ratio schedule of drug self-administration. Unlike MOP receptor agonists, BU08028 at antinociceptive doses and ?10-to 30-fold higher doses did not cause respiratory depression or cardiovascular adverse events as measured by telemetry devices. After repeated administration, the monkeys developed acute physical dependence on morphine, as manifested by precipitated withdrawal signs, such as increased respiratory rate, heart rate, and blood pressure. In contrast, monkeys did not show physical dependence on BU08028. These in vivo findings in primates not only document the efficacy and tolerability profile of bifunctional MOP/NOP receptor agonists, but also provide a means of translating such ligands into therapies as safe and potentially abusefree opioid analgesics.
CitationDing H, Czoty PW, Kiguchi N, Cami-Kobeci G, Sukhtankar DD, Nader MA, Husbands SM, Ko MC (2016) 'A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates', Proceedings of the National Academy of Sciences, 113 (37), pp.E5511-E5518.
PublisherNational Academy of Sciences
PubMed Central IDPMC5027459
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Yellow - can archive pre-print (ie pre-refereeing)
- Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
- Authors: Sukhtankar DD, Zaveri NT, Husbands SM, Ko MC
- Issue date: 2013 Jul
- The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.
- Authors: Khroyan TV, Polgar WE, Cami-Kobeci G, Husbands SM, Zaveri NT, Toll L
- Issue date: 2011 Mar
- [Therapeutic potentials of safe opioid analgesics targeting nociceptin/orphanin FQ peptide receptor].
- Authors: Kiguchi N, Kishioka S, Ko MC
- Issue date: 2021
- Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.
- Authors: Cremeans CM, Gruley E, Kyle DJ, Ko MC
- Issue date: 2012 Oct
- BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.
- Authors: Kiguchi N, Ding H, Cami-Kobeci G, Sukhtankar DD, Czoty PW, DeLoid HB, Hsu FC, Toll L, Husbands SM, Ko MC
- Issue date: 2019 Jun